Borje Andersson
Fortuna: 5 M $ al 31/07/2026
Fortuna: 5 M $ al 31/07/2026
Borje S.
Andersson is currently Director at GreenJay Therapeutics, Inc. since 2022 and Professor at The University of Texas M.D.
Anderson Cancer Center.
Formerly, Dr. Andersson was Executive Director & Chief Medical Officer at Racura Oncology Ltd. in 2020.
Education includes undergraduate studies at Karolinska Institutet.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
RACURA ONCOLOGY LTD 1,93 % | 08/08/2025 | 3.778.577 ( 1,93 % ) | 5 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
| RACURA ONCOLOGY LTD | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
Race Oncology Ltd.
Race Oncology Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.